360 related articles for article (PubMed ID: 26967048)
1. Ivabradine for the treatment of chronic heart failure.
Henri C; O'Meara E; De Denus S; Elzir L; Tardif JC
Expert Rev Cardiovasc Ther; 2016; 14(5):553-61. PubMed ID: 26967048
[TBL] [Abstract][Full Text] [Related]
2. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice.
Zugck C; Martinka P; Stöckl G
Adv Ther; 2014 Sep; 31(9):961-74. PubMed ID: 25160945
[TBL] [Abstract][Full Text] [Related]
3. Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study.
Riccioni G; Masciocco L; Benvenuto A; Saracino P; De Viti D; Massari F; Meliota G; Buta F; Speziale G
Pharmacology; 2013; 92(5-6):276-80. PubMed ID: 24296869
[TBL] [Abstract][Full Text] [Related]
4. Heart rate reduction in heart failure: ivabradine or beta blockers?
Guglin M
Heart Fail Rev; 2013 Jul; 18(4):517-28. PubMed ID: 22972475
[TBL] [Abstract][Full Text] [Related]
5. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
[TBL] [Abstract][Full Text] [Related]
6. Ivabradine and outcomes in chronic heart failure.
Gupta A; Sharma YP
Lancet; 2010 Dec; 376(9758):2069; author reply 2069-70. PubMed ID: 21168044
[No Abstract] [Full Text] [Related]
7. [Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and health related quality of life: results from the SHIFT substudies].
Vítovec J; Spinarová L; Spinar J
Vnitr Lek; 2012; 58(7-8):612-17. PubMed ID: 23067195
[TBL] [Abstract][Full Text] [Related]
8. Advances in the management of heart failure: the role of ivabradine.
Müller-Werdan U; Stöckl G; Werdan K
Vasc Health Risk Manag; 2016; 12():453-470. PubMed ID: 27895488
[TBL] [Abstract][Full Text] [Related]
9. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W
Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314
[TBL] [Abstract][Full Text] [Related]
10. Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study.
Bagriy AE; Schukina EV; Samoilova OV; Pricolota OA; Malovichko SI; Pricolota AV; Bagriy EA
Adv Ther; 2015 Feb; 32(2):108-19. PubMed ID: 25700807
[TBL] [Abstract][Full Text] [Related]
11. Role of ivabradine and heart rate lowering in chronic heart failure: guideline update.
Chow SL; Page RL; Depre C
Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):515-526. PubMed ID: 29902387
[TBL] [Abstract][Full Text] [Related]
12. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
Perry CM
Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
[TBL] [Abstract][Full Text] [Related]
13. Limited role for ivabradine in the treatment of chronic heart failure.
Cullington D; Goode KM; Cleland JG; Clark AL
Heart; 2011 Dec; 97(23):1961-6. PubMed ID: 21917660
[TBL] [Abstract][Full Text] [Related]
14. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure.
Komajda M; Böhm M; Borer J; Ford I; Krum H; Tase A; Tavazzi L; Swedberg K
Eur J Heart Fail; 2013 Jan; 15(1):79-84. PubMed ID: 22892123
[TBL] [Abstract][Full Text] [Related]
15. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
Tondi L; Fragasso G; Spoladore R; Pinto G; Gemma M; Slavich M; Godino C; Salerno A; Montanaro C; Margonato A
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):351-356. PubMed ID: 29762337
[TBL] [Abstract][Full Text] [Related]
16. Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey.
Komajda M; Anker SD; Cowie MR; Filippatos GS; Mengelle B; Ponikowski P; Tavazzi L;
Eur J Heart Fail; 2016 May; 18(5):514-22. PubMed ID: 27095461
[TBL] [Abstract][Full Text] [Related]
17. Is There a Role for Ivabradine in the Contemporary Management of Patients with Chronic Heart Failure in Academic and Community Heart Failure Clinics in Canada?
Roth S; Fernando C; Azeem S; Moe GW
Adv Ther; 2017 Jun; 34(6):1340-1348. PubMed ID: 28432646
[TBL] [Abstract][Full Text] [Related]
18. Ivabradine: Current and Future Treatment of Heart Failure.
Thorup L; Simonsen U; Grimm D; Hedegaard ER
Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):89-97. PubMed ID: 28371247
[TBL] [Abstract][Full Text] [Related]
19. Ivabradine in Management of Heart Failure: a Critical Appraisal.
Orasanu G; Al-Kindi SG; Oliveira GH
Curr Heart Fail Rep; 2016 Feb; 13(1):60-9. PubMed ID: 26797824
[TBL] [Abstract][Full Text] [Related]
20. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice.
Di Franco A; Sarullo FM; Salerno Y; Figliozzi S; Parrinello R; Di Pasquale P; Lanza GA
Am J Cardiovasc Drugs; 2014 Apr; 14(2):101-10. PubMed ID: 24327100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
